Clinical Trial Update: Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases [Phase 2]

View source ↗

Summary

Phase 2 study of tesevatinib in subjects with non-small cell lung cancer and brain or leptomeningeal metastases has completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Leptomeningeal Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• tesevatinib (tesevatinib)

Snippet

Sponsor: Kadmon Corporation, LLC | Conditions: Non-Small Cell Lung Cancer, Leptomeningeal Metastases | Phase 2 | Status: COMPLETED | Results posted: 2021-11-23